Case study – Ghana: Med Safety App in action

Communications / 17 March 2020

Chief Executive of the FDA, Delese Darko delivering the welcome address at the Med Safety App launch in Ghana, 25 June 2019. Photo: Ghana FDA

The Med Safety App was launched in Ghana by a representative of the Honourable Minister of Health on 25 June 2019. The Chief Executive Officer of the Food and Drugs Authority (FDA), Mrs. Delese Darko, gave a warm welcome and expressed optimism that the app will improve ADR reporting rates and improve patient safety in Ghana.

Prior to the launch, the FDA used social media platforms, radio, and television to inform the general public about the importance of the app and raise awareness. Since the launch, distribution of flyers and engagement with professional associations and consumers has continued. For example, a presentation during the Annual General Meeting of the Pharmaceutical Society of Ghana resulted in over 400 downloads of the app.

As of 31 December 2019, six months after the launch, there have been more than 1,500 downloads and 67 ADR reports received through the app – 57 (85%) submitted by healthcare professionals and the remaining 10 (15%) from patients.

Continuous engagement and awareness raising about the benefits of the app are seen as key success factors and currently the FDA is developing strategies, including short videos, to educate patients and healthcare professionals to download and use the app.

Ghana Launch 2
Ghana Launch 3
Ghana Launch 4
Ghana Launch 1

George Sabblah
Head of Safety and Monitoring Department, Ghana FDA

You may also like


When drugs damage the liver– New podcast out now

The liver, responsible for drug metabolism in the body, is also most at risk of damage due to medicines. Unravel the complexities of DILI and its impact on medication safety.

Communications / 05 February 2024

Patient voices in pharmacovigilance takes centre stage at ISoP Bali 2023

The most recent ISoP event saw hundreds of experts gather to explore the latest innovations and challenges facing pharmacovigilance, with a special focus on patient perspectives.

Communications / 16 January 2024

Patient safety set to gain from new partnership between CDISC and UMC

The partnership seeks to improve the interoperability of CDISC standards and WHODrug Global for more effective sharing and use of medicinal product safety data.

Communications / 20 February 2024

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies.

Find out more